Definium Therapeutics Inc(DFTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.44 | Insider Own | 5.49% | Shs Outstand | 134.4M | Perf Week | 8.22% |
| Market Cap | 4.79B | Forward P/E | - | EPS next Y | 35.96% | Insider Trans | -1.86% | Shs Float | 127.0M | Perf Month | -1.35% |
| Enterprise Value | 3.75B | PEG | - | EPS next Q | -0.56 | Inst Own | 84.66% | Short Float | 8.93% | Perf Quarter | -14.97% |
| Income | -0.35B | P/S | - | EPS this Y | -55.18% | Inst Trans | 37.53% | Short Ratio | 5.21 | Perf Half Y | 70.07% |
| Sales | 0.00B | P/B | 5.22 | EPS next 5Y | 25.36% | ROA | -51.35% | Short Interest | 11.34M | Perf YTD | 166.47% |
| Book/sh | 6.84 | P/C | 4.42 | EPS past 3/5Y | -3.78% -1.48% | ROE | -64.09% | 52W High | -28.21% ($49.70) | Perf Year | 188.21% |
| Cash/sh | 8.07 | P/FCF | - | Sales past 3/5Y | - | ROIC | -37.04% | 52W Low | 240.96% ($10.46) | Perf 3Y | 1277.61% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -151.97% | Gross Margin | - | Volatility(W/M) | 4.61% 4.91% | Perf 5Y | 1.22% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.78 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 6.95 | EPS Q/Q | -186.82% | Profit Margin | - | RSI (14) | 47.82 | Recom | 1.05 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.95 | Sales Q/Q | - | SMA20 | 0.45% ($35.52) | Beta | 2.24 | Target Price | $72.56 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/8/6 | SMA50 | -7.16% ($38.43) | Rel Volume | 0.48 | Prev Close | $35.67 |
| Employees | 106 | LT Debt/Eq | 0.04 | EPS/Sales Surpr. | -166.17% - | SMA200 | 22.42% ($29.15) | Avg Volume(3M) | 2.18M | Price | $35.68 |
| IPO | 2016/11/15 | Option/Short | Yes/Yes | Trades | 10520 | Volume | 1,054,138 | Change | 0.03% |
🧬 A clinical-stage biotech company developing treatments for mental health conditions. It develops therapies for brain health disorders such as anxiety and depression and is drawing attention for its progress in late-stage clinical trials. The company is a biotech firm specializing in mental health therapeutics.
Over the past 1 year, roughly in the middle
28% below its 1-year high.
Traded less than usual. That is 48% of its average volume.
DFTX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -55.2% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +1.2%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 84.7%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #53 of 594 in the industry
Based on market cap of $5B.
PTCT#51 PTC Therapeutics Inc $5B PER - 
SRRK#52 Scholar Rock Holding Corp $5B PER - DFTX#53 Definium Therapeutics Inc $5B PER - 
CRSP#54 CRISPR Therapeutics AG $5B PER - 
TVTX#55 Travere Therapeutics Inc $5B PER - 
FAQ
What kind of company is DFTX?
DFTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of DFTX?
The market cap of DFTX is approximately $4.8B, ranking 1,375 within its sector.
What is the 52-week high and low for DFTX?
DFTX has recorded a 52-week high of $49.70 and a low of $10.46.
